Metagenomi (MGX) Competitors $1.41 +0.15 (+11.90%) Closing price 04/4/2025 04:00 PM EasternExtended Trading$1.43 +0.02 (+1.42%) As of 04/4/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MGX vs. OLMA, LFCR, FHTX, ENGN, YMAB, NVCT, MNPR, KRRO, INMB, and ELDNShould you be buying Metagenomi stock or one of its competitors? The main competitors of Metagenomi include Olema Pharmaceuticals (OLMA), Lifecore Biomedical (LFCR), Foghorn Therapeutics (FHTX), enGene (ENGN), Y-mAbs Therapeutics (YMAB), Nuvectis Pharma (NVCT), Monopar Therapeutics (MNPR), Korro Bio (KRRO), INmune Bio (INMB), and Eledon Pharmaceuticals (ELDN). These companies are all part of the "pharmaceutical products" industry. Metagenomi vs. Olema Pharmaceuticals Lifecore Biomedical Foghorn Therapeutics enGene Y-mAbs Therapeutics Nuvectis Pharma Monopar Therapeutics Korro Bio INmune Bio Eledon Pharmaceuticals Olema Pharmaceuticals (NASDAQ:OLMA) and Metagenomi (NASDAQ:MGX) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, profitability, analyst recommendations, dividends, community ranking and media sentiment. Do analysts rate OLMA or MGX? Olema Pharmaceuticals currently has a consensus price target of $27.67, indicating a potential upside of 751.28%. Metagenomi has a consensus price target of $13.00, indicating a potential upside of 821.99%. Given Metagenomi's higher possible upside, analysts plainly believe Metagenomi is more favorable than Olema Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Olema Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Metagenomi 0 Sell rating(s) 1 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 2.80 Does the media prefer OLMA or MGX? In the previous week, Olema Pharmaceuticals had 2 more articles in the media than Metagenomi. MarketBeat recorded 6 mentions for Olema Pharmaceuticals and 4 mentions for Metagenomi. Metagenomi's average media sentiment score of 0.27 beat Olema Pharmaceuticals' score of 0.14 indicating that Metagenomi is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Olema Pharmaceuticals 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral Metagenomi 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Do insiders and institutionals hold more shares of OLMA or MGX? 91.8% of Olema Pharmaceuticals shares are held by institutional investors. 19.4% of Olema Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is OLMA or MGX more profitable? Olema Pharmaceuticals has a net margin of 0.00% compared to Metagenomi's net margin of -134.27%. Metagenomi's return on equity of -43.23% beat Olema Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Olema PharmaceuticalsN/A -53.56% -47.86% Metagenomi -134.27%-43.23%-18.86% Does the MarketBeat Community prefer OLMA or MGX? Olema Pharmaceuticals received 15 more outperform votes than Metagenomi when rated by MarketBeat users. However, 95.45% of users gave Metagenomi an outperform vote while only 70.59% of users gave Olema Pharmaceuticals an outperform vote. CompanyUnderperformOutperformOlema PharmaceuticalsOutperform Votes3670.59% Underperform Votes1529.41% MetagenomiOutperform Votes2195.45% Underperform Votes14.55% Which has more volatility & risk, OLMA or MGX? Olema Pharmaceuticals has a beta of 2.11, suggesting that its share price is 111% more volatile than the S&P 500. Comparatively, Metagenomi has a beta of -0.27, suggesting that its share price is 127% less volatile than the S&P 500. Which has stronger earnings and valuation, OLMA or MGX? Metagenomi has higher revenue and earnings than Olema Pharmaceuticals. Olema Pharmaceuticals is trading at a lower price-to-earnings ratio than Metagenomi, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOlema PharmaceuticalsN/AN/A-$96.65M-$2.21-1.47Metagenomi$52.30M1.01-$68.25M-$2.62-0.54 SummaryMetagenomi beats Olema Pharmaceuticals on 9 of the 17 factors compared between the two stocks. Remove Ads Get Metagenomi News Delivered to You Automatically Sign up to receive the latest news and ratings for MGX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MGX vs. The Competition Export to ExcelMetricMetagenomiBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$52.71M$2.83B$5.24B$7.07BDividend YieldN/A1.53%4.87%4.05%P/E Ratio-0.5429.1621.1817.48Price / Sales1.01420.20356.3585.27Price / CashN/A168.6838.1634.64Price / BookN/A3.486.233.79Net Income-$68.25M-$72.06M$3.20B$247.10M7 Day Performance-4.73%-12.92%-8.32%-7.32%1 Month Performance-23.78%-20.23%-3.36%-10.19%1 Year Performance-86.03%-34.36%2.72%-7.41% Metagenomi Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MGXMetagenomi1.6335 of 5 stars$1.41+11.9%$13.00+822.0%-86.0%$52.71M$52.30M-0.54236Analyst ForecastOLMAOlema Pharmaceuticals2.4926 of 5 stars$4.34+2.5%$27.50+534.4%-69.1%$247.24MN/A-1.9770Gap DownLFCRLifecore Biomedical2.1301 of 5 stars$6.59+0.6%$8.00+21.4%-13.6%$244.00M$130.86M-11.77690Earnings ReportNews CoverageGap DownFHTXFoghorn Therapeutics1.8742 of 5 stars$4.22+4.1%$13.17+212.4%-51.2%$233.29M$22.60M-2.18120ENGNenGene2.9172 of 5 stars$4.58-7.8%$25.22+451.3%-72.6%$233.22MN/A-7.8931YMABY-mAbs Therapeutics3.7723 of 5 stars$5.15+2.9%$18.30+255.7%-68.8%$231.06M$87.69M-9.46150NVCTNuvectis Pharma2.3007 of 5 stars$9.81-3.9%$15.00+53.0%+7.0%$229.48MN/A-8.468Analyst ForecastNews CoverageMNPRMonopar Therapeutics2.2402 of 5 stars$37.40-6.5%$44.00+17.6%+839.8%$228.22MN/A-18.9810Earnings ReportAnalyst ForecastInsider TradeAnalyst RevisionNews CoverageKRROKorro Bio1.3444 of 5 stars$24.26+2.1%$142.57+487.8%-79.9%$226.36M$2.27M-2.5770INMBINmune Bio1.528 of 5 stars$8.30+2.2%$22.80+174.9%-29.1%$221.37M$42,000.00-3.8210ELDNEledon Pharmaceuticals1.3874 of 5 stars$3.60+2.5%$12.50+247.5%+60.8%$216.91MN/A-1.8110Gap Up Remove Ads Related Companies and Tools Related Companies Olema Pharmaceuticals Competitors Lifecore Biomedical Competitors Foghorn Therapeutics Competitors enGene Competitors Y-mAbs Therapeutics Competitors Nuvectis Pharma Competitors Monopar Therapeutics Competitors Korro Bio Competitors INmune Bio Competitors Eledon Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MGX) was last updated on 4/5/2025 by MarketBeat.com Staff From Our Partners“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredAmerica’s Retirement Accounts Are at Risk—Here’s WhyWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredTrump’s Final Plan Presidential insider exposes shocking plot to reshape U.S. economy: The 2025 Trump Reset -- Inside Trump’...Porter & Company | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredIt’s Time to Buy Elon’s “ChatGPT Killer”Elon Musk’s new AI model is blowing everyone’s mind. It has been called “a game-changer in AI innovation”.....Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Metagenomi, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Metagenomi With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy MGX Stock Free MGX Stock Alerts